Role of p53 Expression in the Progression of Gastric Cancer in the Indian Population
Downloads
Introduction: Gastric carcinogenesis frequently affects tumor suppressor TP53 gene, resulting in increased expression of p53 protein and mutations towards later stages of Gastric Carcinoma. Objectives: To analyze p53 protein expression in different stages of gastric cancer to determine if it could be used as a biomarker to allow targeted screening of high risk groups with intestinal metaplasia.
Methods: We retrieved 101 formalin fixed paraffin embedded tissue blocks of histopathology proven Gastric Carcinoma specimens and conducted an immunohistochemical study on a subset of 25 cases. Tumor sections were taken with adjacent normal mucosa. p53 expression was evaluated using immunohistochemical markers. With the observations from the study, analysis of p53 expression in different areas of the mucosa was done.
Result: Thirteen carcinoma cases (52%) expressed p53 protein with a majority of eight (66.7%) cases showing intensity 3. Normal and metaplastic mucosa did not express p53 protein. In dysplastic mucosa, seven (28%) cases showed p53 expression with intensity ranging from 1 to 3. On comparing the data after excluding the p53 negative regions of normal and metaplastic mucosa, there was no difference with statistical significance.
Conclusion: p53 expression is negative in normal and metaplastic gastric mucosa but shows expression in dysplastic and cancer cells. Thus, TP53 mutation is most likely an event towards later stages of carcinogenesis. We are dubious on the ability of p53 to be used as an authentic screening tool at the metaplastic stage to predict progression to carcinoma.
Busuttil RA, Zapparoli GV, Haupt S, Fennell C, Wong SQ, Pang JM, Takeno EA, Mitchell C, Di Costanzo N, Fox S, Haupt Y, Dobrovic A, Boussioutas A. Role of p53 in the progression of gastric cancer. Oncotarget. 2014 Dec 15; 5(23):12016-26.
Liu KS, Wong IO, Leung WK. Helicobacter pylori associated gastric intestinal metaplasia: Treatment and surveillance. World J Gastroenterol. 2016;22(3):1311-1320.
Wei, N., Zhou, M., Lei, S. et al. A meta-analysis and systematic review on subtypes of gastric intestinal metaplasia and neoplasia risk. Cancer Cell Int.2021; 21: 173.
Tahara T, Shibata T, Okamoto Y, et al. Mutation spectrum of TP53 gene predicts clinicopathological features and survival of gastric cancer. Oncotarget. 2016; 7(27):42252-42260.
Günther T, Schneider-Stock R, Häckel C, Kasper HU, Pross M, Hackelsberger A, Lippert H, Roessner A. Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations. Mod Pathol. 2000 Jun;13(6):621-6.
González CA, Sanz-Anquela JM, Gisbert JP, Correa P. Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence. Int J Cancer. 2013 Sep 1;133(5):1023-32.
Wu MS, Shun CT, Lee WC, et al. Overexpression of p53 in different subtypes of intestinal metaplasia and gastric cancer. Br J Cancer. 1998;78(7):971-973.
C. M. Servarayan , A. Chandramohan , D. Datta , K. Manickavasagam. p53 and its influence in adenocarcinoma stomach. Journal of Clinical Oncology.2009;27:15.
Guo P, Li Y, Zhu Z, Sun Z, Lu C, Wang Z, Xu H. Prognostic value of tumor size in gastric cancer: an analysis of 2,379 patients. Tumour Biol. 2013 Apr;34(2):1027-35.
Zabaleta J. Multifactorial etiology of gastric cancer. Methods Mol Biol. 2012;863:411-35.
Bellini MF, Cadamuro AC, Succi M, Proença MA, Silva AE. Alterations of the TP53 gene in gastric and esophageal carcinogenesis. J Biomed Biotechnol. 2012;2012:891961.
Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988 Jul 1;48(13):3554-60.
Busuttil RA, Boussioutas A. Intestinal metaplasia: a premalignant lesion involved in gastric carcinogenesis. J Gastroenterol Hepatol. 2009 Feb;24(2):193-201.
Joypaul BV, Newman EL, Hopwood D, Grant A, Qureshi S, Lane DP, Cuschieri A. Expression of p53 protein in normal, dysplastic, and malignant gastric mucosa: an immunohistochemical study. J Pathol. 1993 Jul;170(3):279-83.
César AC, Borim AA, Caetano A, Cury PM, Silva AE. Aneuploidies, deletion, and overexpression of TP53 gene in intestinal metaplasia of patients without gastric cancer. Cancer Genet Cytogenet. 2004 Sep;153(2):127-32.
Silva TC, Leal MF, Calcagno DQ, de Souza CR, Khayat AS, dos Santos NP, Montenegro RC, Rabenhorst SH, Nascimento MQ, Assumpção PP, de Arruda Cardoso Smith M, Burbano RR. hTERT, MYC and TP53 deregulation in gastric preneoplastic lesions. BMC Gastroenterol. 2012 Jul 6;12:85.
Lee WJ, Shun CT, Hong RL, Wu MS, Chang KJ, Chen KM. Overexpression of p53 predicts shorter survival in diffuse type gastric cancer. Br J Surg. 1998 Aug;85(8):1138-42.
Wei K, Jiang L, Wei Y, Wang Y, Qian X, Dai Q, Guan Q. The prognostic significance of p53 expression in gastric cancer: a meta-analysis. J Cancer Res Clin Oncol. 2015 Apr;141(4):735-48.
All Content should be original and unpublished.
